Description
Adding elotuzumab to standard treatment for multiple myeloma delays disease progression
- You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart
Article: Adding elotuzumab to standard treatment for multiple myeloma delays disease progression
€2.42
Related products
-
Article: Highlights in urologic cancer
€2.42 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€2.42 Add to cart -
Article: Highlights in breast cancer
€2.42 Add to cart -
1 year access Online Belgian Journal of Hematology (BJH)
€43.60 Add to cart
Reviews
There are no reviews yet.